Imbalance of Hypoxia-Inducible Factors Involved in the Drug Resistance of Sunitinib treatment in Renal Cell Carcinoma
碩士 === 國防醫學院 === 生物及解剖學研究所 === 100 === Renal cell carcinoma (RCC) is an angiogenesis-dependent disease and highly resistant to chemo- and radiation therapies. Therefore, anti-angiogenesis therapy has emerged as a pivotal treatment of metastatic RCC. Tyrosine kinases are important cellular signaling...
Main Authors: | Liu, Shu-Yu, 劉書瑜 |
---|---|
Other Authors: | Cha, Tai-Lung |
Format: | Others |
Language: | zh-TW |
Published: |
2012
|
Online Access: | http://ndltd.ncl.edu.tw/handle/77745891344857014723 |
Similar Items
-
Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01) -
Sunitinib in the treatment of metastatic renal cell carcinoma
by: Thomas A. Schmid, et al.
Published: (2016-12-01) -
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
by: Manuela Schmidinger, et al.
Published: (2012-10-01) -
Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway
by: Luchao Li, et al.
Published: (2021-02-01) -
Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
by: Nanna Bæk Møller, et al.
Published: (2019-09-01)